# Rapport Therapeutics Inc.: Phase 2 study completed, 253 enrolled (Bipolar 1 Disorder)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Rapport Therapeutics Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder |
| NCT ID | NCT07046494 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Bipolar 1 Disorder |
| Intervention types | drug, other |
| Target enrollment | 253 |
| Site countries | United States |
| Posted | 2025-07-01 |
| Planned start | 2025-07-25 |
| Event | Completed |
| Event date | 2026-09-24 |
| Last update posted | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.
- 253 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07046494). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.